SJS Investment Consulting
SPRY icon

SJS Investment Consulting’s ARS Pharmaceuticals SPRY Stock Holding History

SJS Investment Consulting’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22 Buy
5
+4
+400% +$23 ﹤0.01% 3169
2026
Q2 		$9 Buy
+1
New +$9 ﹤0.01% 2860

Other funds holding SPRY

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
General American Investors
General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Investment Management Associates
Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return
Levin Capital Strategies
Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SJS Investment Consulting's SPRY Position: Q3 2026 in Review

SJS Investment Consulting increased its ARS Pharmaceuticals (SPRY) stake by 400% in Q3 2026, buying an estimated $23 and bringing the position to 5 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #3169.

SJS Investment Consulting first reported a position in SPRY in Q2 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • SJS Investment Consulting held 5 shares of ARS Pharmaceuticals worth $22 as of Q3 2026.
  • SJS Investment Consulting bought 4 ARS Pharmaceuticals shares in Q3 2026, an estimated $23.
  • ARS Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #3169 holding.
  • SJS Investment Consulting first reported a position in ARS Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.